Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179568 | 1.00 | ADRB2 (0.32) | ADRB2CYP3A4ALDH1A1CDK2 | |
| SCHEMBL20094443 | 1.00 | ADRB2 (0.32) | ADRB2CYP3A4ALDH1A1CDK2 | |
| SCHEMBL1666884 | 0.75 | ALDH1A1 (0.54) | ADRB2CYP3A4ALDH1A1 | |
| SCHEMBL10426802 | 0.73 | ALDH1A1 (0.58) | CYP3A4ALDH1A1 | |
| SCHEMBL1106341 | 0.73 | ALDH1A1 (0.58) | CYP3A4ALDH1A1 | |
| SCHEMBL25431109 | 0.73 | ALDH1A1 (0.48) | CYP3A4ALDH1A1 | |
| SCHEMBL19216710 | 0.73 | ALDH1A1 (0.48) | CYP3A4ALDH1A1 | |
| SCHEMBL2201612 | 0.73 | ALDH1A1 (0.58) | CYP3A4ALDH1A1 | |
| SCHEMBL4944901 | 0.71 | ADRB2 (0.33) | ADRB2CYP3A4 | |
| SCHEMBL23517238 | 0.70 | ADRB2 (0.34) | ADRB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-117545356-A | Heterocyclic compound and method for controlling drug-resistant harmful arthropods by using composition containing same | 住友化学株式会社 | 2024-02-09 | — | — | CN | disclosed |
| CN-111278821-B | Spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3704114-B1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220242858-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-08-04 | — | — | US | disclosed |
| EP-3730487-B1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | GILEAD SCIENCES INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20190315729-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2019-10-17 | — | — | US | disclosed |
| US-10329286-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| EP-3468962-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017218337-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-7960552-B2 | 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid and the potassium salt; antidiabetic agents; improved glucose tolerance and decreased insulin resistance | GLAXOSMITHKLINE LLC (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120775-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | ADRB2 73/4885CYP3A4 110/4885ALDH1A1 2326/4885 |
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | ADRB2 275/4885CYP3A4 448/4885ALDH1A1 2649/4885 |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | ADRB2 1061/4885CYP3A4 1126/4885ALDH1A1 3805/4885 |
| US-10329286-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | ADRB2 1061/4885CYP3A4 1126/4885ALDH1A1 3805/4885 |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | ADRB2 1061/4885CYP3A4 1126/4885ALDH1A1 3805/4885 |
| US-20220242858-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | ADRB2 1061/4885CYP3A4 1126/4885ALDH1A1 3805/4885 |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | ADRB2 739/4885CYP3A4 141/4885ALDH1A1 2656/4885 |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | NR1H2, NR1H4, NR1H3 | ADRB2 168/4885CYP3A4 375/4885ALDH1A1 1437/4885 |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | ADRB2 88/4885CYP3A4 914/4885ALDH1A1 2984/4885 |
| US-20190315729-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | ADRB2 1061/4885CYP3A4 1126/4885ALDH1A1 3805/4885 |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | ADRB2 73/4885CYP3A4 110/4885ALDH1A1 2326/4885 |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | ADRB2 1061/4885CYP3A4 1126/4885ALDH1A1 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.